Greenwood Gearhart Inc. Lowers Stock Position in Johnson & Johnson $JNJ

Greenwood Gearhart Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 4,855 shares of the company’s stock after selling 126 shares during the period. Greenwood Gearhart Inc.’s holdings in Johnson & Johnson were worth $742,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $35,000. Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $48,000. Finally, von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research report on Friday. Morgan Stanley lifted their price target on Johnson & Johnson from $176.00 to $178.00 and gave the stock an “equal weight” rating in a research report on Friday. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Bank of America lifted their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, UBS Group set a $198.00 price objective on Johnson & Johnson in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Johnson & Johnson Price Performance

NYSE JNJ opened at $190.66 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $192.10. The stock has a 50-day moving average of $178.48 and a 200 day moving average of $163.78. The company has a market capitalization of $459.16 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.